Clinical Trial Update: Gene Therapy for Metachromatic Leukodystrophy (MLD) [Phase 1, Phase 2]

View source ↗

Summary

A gene therapy trial for Metachromatic Leukodystrophy (MLD) in Phase 1/2 has completed the study, sponsored by Orchard Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metachromatic Leukodystrophy

Snippet

Sponsor: Orchard Therapeutics | Conditions: Lysosomal Storage Disease, Metachromatic Leukodystrophy | Phase 1, Phase 2 | Status: COMPLETED